The Potential of Differentiation-Related Gene-1 (DRG1) as a Biomarker for Metastasis of Estrogen Receptor-Positive Breast Cancer
Journal of Advances in Medicine and Medical Research,
Introduction: Breast cancer is major burden worldwide and the majority of breast cancers express estrogen receptors (ER) suggesting a high dependence on estrogen hormone. Age is among the major determinants of breast cancer development, however, although Western Kenya is one of the areas with high breast cancer cases, age distribution of ER-positive breast cancer in the sub-region remains largely undocumented. Differentiation-related gene-1 (DRG1) is a metastasis suppressor and thus a potential biomarker for predicting level of metastasis but its potential application in assessing extent of metastasis of ER positive breast cancer has not been fully explored. This study therefore investigated the age distribution and the potential of expression of DRG1 in assessing metastasis of ER positive breast cancer.
Materials and Methods: Breast cancer tumour blocks archived in safe cabins in the histology laboratory section, Moi Teaching and Referral hospital, Eldoret, Kenya were used. Clinico-pathological parameters such as histology grade, tumor size, which are associated with metastatic cancer, were assessed using the archived clinico-pathological reports and/or histological analysis of the tumour blocks. Expression of DRG1 and Ki-67 proteins were determined using immunohistochemistry.
Results: ER positive breast cancer was predominant among women aged 40 and 50 years. No association was observed between immunohistochemical expression of DRG1 and parameters such as histology grade, tumor size or expression of Ki-67 protein expressed DRG1 (p > 0.05).
Conclusion: The findings suggest that expression of DRG1 protein is not associated with parameters that indicate breast cancer metastasis. Thus, DRG1 expression is not a potential biomarker candidate for ER positive breast cancer metastasis. However, since the small sample size was used, further research using larger prospective study is necessary to support the present findings.
- Differentiation related gene-1 (DRG1)
- estrogen receptor positive breast cancer; western kenya
How to Cite
(Accessed July 29, 2019).
Naanyu V, Asirwa C, Wachira J, Busakhala N, Kisuya J, OG. Lay perceptions of breast cancer in Western Kenya. World J Clin Oncol . 2015;6:147–55.
Ministry of Health Kenya, Kenya National Cancer Screening Guidelines. Minist Heal Kenya; 2018.
(Accessed April 29, 2019).
Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer. J Clin Invest. 2010;120:2406–13.
Clarke R, Tyson J, Dixon J. Endocrine resistance in breast cancer – An overview and update. Mol Cell Endocrinol. 2015; 418:220–34.
Johnston S. Targeted combinations for hormone receptor–positive advanced breast cancer: who benefits? J Clin Oncol. 2016;34:393–5.
Su Y, Zheng Y, Gu K, Chen Z, Li G. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: A population-based cohort study. BMC Cancer. 2011;11:292.
Anyanwu S. Breast Cancer in Eastern Nigeria: A Ten Year Review. West Afr J Med. 2000;19:120–5.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin D. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–917.
Parkin D, Bray F, Ferlay J, Jemal A. Cancer in Africa 2012. Cancer Epidemiol Biomarkers Prev. 2014;23:953–66.
Sawe R, Kerper M, Badve S, Li J, Sandoval-Cooper M, Xie J. Aggressive breast cancer in Western Kenya has early onset, high proliferation, and immune cell infiltration. BMC Cancer. 2016;16:1–15.
Zhang XF, Giuliano M, Trivedi M, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19:1–16.
Baig R, Sanders A, Kayani M, Jiang W. Association of differentiation-related gene-1 (DRG1) with breast cancer survival and in vitro impact of DRG1 suppression. Cancers (Basel). 2012;4:658–72.
Bandyopadhyay S, Pai S, Hirota S, Hosobe S, Takano Y, Saito K. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene. 2004;23:5675–5681.
Kobayashi T, Iwaya K, Moriya T, Yamasaki T, Tsuda H, Yamamoto J. A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol. 2013;13:1–13.
Rakha E, Reis-Filho J, Baehner F, Dabbs D, Decker T, Eusebi V. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12:1–12.
Fotovati A, Fujii T, Yamaguchi M, Kage M, Shirouzu K, Oie S. 17β-estradiol induces down-regulation of Cap43/NDRG1/Drg-1, a putative differentiation-related and metastasis suppressor gene, in human breast cancer cells. Clin Cancer Res. 2006;12:3010–8.
Li X, Huang J, Yi P, Bambara R, Hilf R, Muyan M. Single-chain estrogen receptors (ERs) reveal that the ERα/β heterodimer emulates functions of the ERα dimer in genomic estrogen signaling pathways. Mol Cell Biol. 2004;24:7681–94.
Ademuyiwa FO, Groman A, Hong CC, Miller A, Kumar S, Levine E, et al. Time-trends in survival in young women with breast cancer in a SEER population-based study. Breast Cancer Res Treat. 2013;138:241–8.
Gupta PB, Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol. 2006;102:71–8.
Wiencke J. Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer. 2004;4:79.
Abstract View: 82 times
PDF Download: 73 times